EN | UA
EN | UA

Help Support

Back

Booster vaccination with inactivated SARS-CoV-2 vaccine is safe and immunogenic

COVID-19 COVID-19
COVID-19 COVID-19

What's new?

In healthy adults, a booster vaccination with an inactivated SARS-CoV-2 vaccine showed good safety and immunogenicity.

In a phase Ⅱ trial, one booster vaccination of an inactivated SARS-CoV-2 vaccine given six months following primary vaccination demonstrated good safety and immunogenicity in healthy adults aged 18 to 59 years. Investigators undertook this study to determine safety and immunogenicity of a booster vaccination with an inactivated SARS-CoV-2 vaccine.

The study included 200 healthy adults aged 18-59 years (pregnant and not breastfeeding females were excluded). The primary vaccination schedule groups (50 subjects in each group) were: (i) 0-14 d 5 μg, (ii) 0-14 d 10 μg, (iii) 0-28 d 5 μg, and (iv) 0-28 d 10 μg, respectively. Subjects who had received two-doses primary vaccination were chosen in ascending order of the study number.

They were vaccinated with a booster dose (similar dosage as primary vaccination) at the 6th month following primary vaccination (thirty-day window period). Collection of blood samples was done prior to and after boosting, followed by testing for the geometric mean titers and seroconversion of live virus neutralizing antibody, receptor-binding-domain IgG antibody, and pseudovirus neutralizing antibody.

Within 28 days after boosting, adverse events were examined. The live virus neutralizing antibody geometric mean titers (95%CI) in group 0-14 d 5 μg, 0-14 d 10 μg, 0-28 d 5 μg and 0-28 d 10 μg elevated from 4.07 (3.30-5.04), 3.75 (3.08-4.55), 8.33 (7.01-11.11) and 7.69 (6.19-9.57) prior to the booster vaccination to 284.84 (215.28-376.86), 233.05 (178.61-304.08), 274.81 (223.64-337.68) and 280.77 (234.59-336.04) in twenty-eight days following booster vaccination, respectively.

In all four groups, the rates of live virus neutralizing antibody seroconversion were 100%. The occurrence of adverse events after booster vaccination were 18% (9 cases), 4% (2 cases), 12% (6 cases), and 12% (6 cases) in the four groups. No serious adverse event was noted and no adverse event was graded as level 3 or worse. Thus, booster vaccination with an inactivated SARS-CoV-2 vaccine exhibits a good safety and immunogenicity profile in healthy people.

Source:

Zhonghua Yi Xue Za Zhi

Article:

[Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years]

Authors:

H X Pan et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: